Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
This study has been completed.
First Posted: June 6, 2008
Last Update Posted: March 23, 2012
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2011|
|Primary Completion Date:||November 2011 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Soria JC, LoRusso P, Bahleda R, Lager J, Liu L, Jiang J, Martini JF, Macé S, Burris H. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors. Oncologist. 2015 Mar;20(3):245-6. doi: 10.1634/theoncologist.2014-0449. Epub 2015 Feb 10.